For example, 2, 5-diaminobenzoxazole derivatives show good anti-inflammatory activity in the RA model, in which compound 3e has an inhibition rate of 71.5% on IL-6/STAT3 pathway, and compound 3a has an inhibition rate of IL-1β of 92.1%, and inhibition of these factors improves RA, so such compounds are expected to become drugs for the treatment of RA (269). This evidence concerns the gene STAT3 and rheumatoid arthritis.